Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kintor Pharmaceutical Ltd (HK:9939)
HKEX:9939
Holding HK:9939?
Track your performance easily
9939 Stock Chart & Stats
Day’s RangeHK$0 - HK$0
52-Week RangeHK$0.79 - HK$3.60
Previous CloseHK$0.93
Volume382.00K
Average Volume (3M)392.97K
Market Cap
HK$409.47M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Mar 21, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.27
Shares OutstandingN/A
10 Day Avg. Volume526,900
30 Day Avg. Volume392,968
Standard Deviation0.37
R-Squared0.00119
Alpha0.00732
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)53.84
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Kintor Pharmaceutical Ltd News
PremiumCompany Announcements
Kintor Pharma Reports Reduced Loss, Advances R&D
PremiumCompany Announcements
Kintor Pharma Chairman’s Bold Share Purchase
PremiumCompany Announcements
Kintor Pharma Launches Innovative Anti-Hair Loss CosmeticPremiumCompany Announcements
Kintor Pharmaceutical Announces Board Update
PremiumCompany Announcements
Kintor Pharmaceutical AGM Concludes with Unanimous Votes
PremiumCompany Announcements
Kintor Advances Novel Acne Treatment into Phase II Trials
PremiumCompany Announcements
Kintor Pharma’s Cosmetic Ingredient Gains Global Recognition
PremiumCompany Announcements
Kintor Pharma Advances AGA Treatment TrialsOptions Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
1.85% Mutual Funds
0.03% Other Institutional Investors
98.12% Public Companies and
Individual Investors
9939 FAQ
What was Kintor Pharmaceutical Ltd’s price range in the past 12 months?
Kintor Pharmaceutical Ltd lowest stock price was HK$0.79 and its highest was HK$3.60 in the past 12 months.
What is Kintor Pharmaceutical Ltd’s market cap?
Currently, no data Available
When is Kintor Pharmaceutical Ltd’s upcoming earnings report date?
Kintor Pharmaceutical Ltd’s upcoming earnings report date is Mar 21, 2025 which is in 182 days.
How were Kintor Pharmaceutical Ltd’s earnings last quarter?
Kintor Pharmaceutical Ltd released its earnings results on Aug 26, 2024. The company reported -HK$0.187 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.187.
Is Kintor Pharmaceutical Ltd overvalued?
According to Wall Street analysts Kintor Pharmaceutical Ltd’s price is currently Overvalued.
Does Kintor Pharmaceutical Ltd pay dividends?
Kintor Pharmaceutical Ltd does not currently pay dividends.
What is Kintor Pharmaceutical Ltd’s EPS estimate?
Kintor Pharmaceutical Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kintor Pharmaceutical Ltd have?
Kintor Pharmaceutical Ltd has 447,499,600 shares outstanding.
What happened to Kintor Pharmaceutical Ltd’s price movement after its last earnings report?
Kintor Pharmaceutical Ltd reported an EPS of -HK$0.187 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.151%.
Which hedge fund is a major shareholder of Kintor Pharmaceutical Ltd?
Currently, no hedge funds are holding shares in HK:9939
---
Kintor Pharmaceutical Ltd Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-107.46%
Trailing 12-Months
Asset Growth
-60.70%
Trailing 12-Months
Company Description
Kintor Pharmaceutical Ltd
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China focused on the proprietary R&D of drugs for cancers and other AR-related diseases. The company's drug candidate, Pruxelutamide, is a drug undergoing phase III clinical trials in China and phase III clinical trials in the United States for mCRPC as well as clinical trials for breast cancer. Its pipeline of seven drug candidates includes Pruxelutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Detorsertib (GT0486), Hedgehog/SMO Inhibitor (GT1708F), PD-L1/TGF-ß (GT90008), and AR-PROTAC Compound (GT20029). It operates in a single segment focusing on research and development of medicine products.
---
Technical Analysis
Akeso, Inc.
―
Wah Wo Holdings Group Limited
―
Alphamab Oncology
―
InnoCare Pharma Ltd.
―
---